Stock Events

Stock Events

Tango Therapeutics 

$20.94
0
+$0.65+3.2% Wednesday 04:28

Statistics

Day High
20.97
Day Low
19.38
52W High
-
52W Low
-
Volume
209
Avg. Volume
-
Mkt Cap
2.82B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.32
-0.17
-0.01
0.14
Expected EPS
-0.3137
Actual EPS
N/A

Financials

-309.73%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
84.14MRevenue
-260.6MNet Income

Analyst Ratings

$21.00Average Price Target
The highest estimate is 30.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNGX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Tango Therapeutics' approach to targeting cancer.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the CRISPR gene editing sector, offering technologies that could rival Tango's cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics focuses on base editing, a form of gene editing that could offer alternative treatments to those developed by Tango.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same therapeutic areas as Tango.
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Allogene Therapeutics is focused on allogeneic CAR T-cell therapies, which could be in direct competition with Tango's cancer treatment approaches.
Fate Therapeutics
FATE
Mkt Cap141.84M
Fate Therapeutics is working on programmed cellular immunotherapies, which could compete with Tango's cancer treatment strategies.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad portfolio, including advanced therapies that could compete with Tango's cancer treatments.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in cell therapy for cancer, competing with Tango Therapeutics.

About

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US87583X1090

Listings

XNAS
US
TNGX
BOATS
BOATS
TNGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tango Therapeutics stock price today?▼
The current price of TNGX.BOATS is $20.94 USD — it has increased by +3.2% in the past 24 hours. Watch Tango Therapeutics stock price performance more closely on the chart.
What is Tango Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tango Therapeutics stocks are traded under the ticker TNGX.BOATS.
What is Tango Therapeutics market cap?▼
Today Tango Therapeutics has the market capitalization of 2.82B
When is the next Tango Therapeutics earnings date?▼
Tango Therapeutics is going to release the next earnings report on May 13, 2026.
What were Tango Therapeutics earnings last quarter?▼
TNGX.BOATS earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.32 USD resulting in a +8.86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tango Therapeutics revenue for the last year?▼
Tango Therapeutics revenue for the last year amounts to 84.14M USD.
What is Tango Therapeutics net income for the last year?▼
TNGX.BOATS net income for the last year is -260.6M USD.
When did Tango Therapeutics complete a stock split?▼
Tango Therapeutics has not had any recent stock splits.